Do elevated tumor markers require regular follow-up?

Elevated tumor markers usually require regular follow-up, and the specific frequency of follow-up should be comprehensively evaluated based on the type of marker, the magnitude of elevation, and individual risk factors.

Tumor markers are biomolecules that reflect the presence or activity of tumors, but their elevation is not necessarily caused by tumors. inflammation, infection, benign lesions, or physiological changes can all lead to transient elevation of biomarkers. If mild elevation is detected during the first test, it is recommended to have a follow-up examination 1-3 months later to observe dynamic changes. Continuous elevation requires further investigation through imaging examinations. For individuals at high risk of cancer or with a history of previous tumors, even if there is a slight increase in biomarkers, the follow-up interval should be shortened to 1-2 months. Some biomarkers such as CEA and CA19-9 have shorter half lives, and the review period can be more intensive. In rare cases, when the biomarker significantly increases by several times the normal value and is accompanied by related symptoms, it is necessary to immediately complete enhanced CT, PET-CT and other examinations. For patients with hereditary tumor syndrome or carriers of specific gene mutations, biomarker monitoring needs to be included in long-term follow-up plans. Certain markers such as PSA are affected by prostate massage and other procedures, and interference factors should be avoided before re examination.

During the follow-up period, it is recommended to maintain a regular schedule and avoid excessive fatigue. A balanced diet is recommended, limiting the intake of red meat and processed foods. Moderate exercise helps maintain immune homeostasis, but it is important to avoid the potential impact of vigorous exercise on test results. Try to conduct each follow-up examination at the same medical institution to ensure consistency in testing methods. If the biomarker shows progressive increase or is accompanied by symptoms such as weight loss and pain, timely medical attention should be sought from the oncology department.